Please try another search
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
Name | Age | Since | Title |
---|---|---|---|
Morris Karmazyn | - | - | Member of Scientific Advisory Board |
A. Michael Lincoff | - | 2005 | Member of Scientific Advisory Board |
Jeffrey Weitz | - | - | Member of Scientific Advisory Board |
Paul W. Armstrong | - | - | Chairman of Scientific Advisory Board |
Peter C. Quick | 67 | 2005 | Independent Director |
Pierre Theroux | - | - | Member of Scientific Advisory Board |
Stephen Hanessian | - | - | Member of Scientific Advisory Board |
Trevor Hassell | - | - | Member of Scientific Advisory Board |
Brent Fawkes | 54 | 2013 | Independent Director |
Arnold Naimark | 90 | 2000 | Independent Director |
Albert David Friesen | 77 | 1997 | Founder, CEO & Chairman of the board |
James F. Kinley | 46 | 2011 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review